Clinical Trial Update: Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)

View source ↗

Summary

Pre-approval single-patient expanded access update for Elranatamab (PF-06863135) in multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Elranatamab (elranatamab)

Snippet

Sponsor: Pfizer | Conditions: Multiple Myeloma | Status: NO_LONGER_AVAILABLE